Monash University is proud to announce the establishment of Resseptor Therapeutics (Resseptor), an innovative biotech spinout aimed at revolutionising the treatment of autoimmune diseases and cancer.
With a seed investment of AUD$2.25 million led by IP Group Australia, a renowned venture capital group focused on early-stage technology investment, Resseptor is poised to drive advancements in developing therapeutics for unmet needs in the treatment of autoimmune disease and oncology. This marks the sixth Monash-led spinout created with investment from IP Group.
Resseptor is set to transform the treatment of inflammatory conditions through its pioneering platform technology, which enhances the immune system’s ability to identify and respond to tissues, malignancies and pathogens. Its core intellectual property stems from the seminal discoveries made by a talented team of scientists during their tenure at Monash University. Monash Innovation has licensed the vital intellectual property to Resseptor, fostering a strong partnership across the scientific founders at Monash University, QUT and La Trobe University.
Dr Stephen Daley, along with a team of researchers, made the discovery during his tenure at Monash University within the Biomedical Discovery Institute. He is now an esteemed immunologist based within QUT’s Centre for Immunology and Infection Control and co-founding scientist at Resseptor.
Dr Daley expressed his enthusiasm, stating, “Resseptor is an example of how an idea and a compelling challenge brings individual researchers, universities, and investors together.The combination of our underlying technology, team and investment support gives us an opportunity to develop a potentially transformative treatment for some of the most challenging inflammatory conditions.”
Senior Director of Commercialisation at Monash Innovation Dr Katherine Nielsen highlighted the significance of this collaboration.
“Resseptor is an example of the translation of impactful inventions emerging from Monash researchers tackling the great challenges in treating inflammatory diseases, an area of expertise in the Faculty of Medicine, Nursing and Health Sciences,” Dr Nielsen said.
Senior Investment Manager at IP Group Australia and Director of Resseptor Dr Alisa Selimovic shared her excitement about the project.
“We are excited to bring together a world-leading team at Resseptor and support cutting-edge Australian research that has the potential for global impact. We are looking forward to sharing Resseptor’s progress as the company advances through proof-of-concept studies,” Dr Selimovic said.
